WuXi Biologics: Expected full-year net profit of 4.91 billion yuan in 2025, a year-on-year increase of 46.3%

2026-02-12 00:24:33

Abstract generation in progress

WuXi Biologics announced on the Hong Kong Stock Exchange that, compared to the same period last year, the company’s full-year revenue as of December 31, 2025, is expected to increase by approximately 16.7% to RMB 21,790 million; gross profit margin will improve by about 5 percentage points to 46.0%; adjusted gross profit will grow to approximately RMB 10,638 million, a year-over-year increase of about 25.5%; for the full year ending December 31, 2025, profit and profit attributable to shareholders will increase by approximately 45.3% to RMB 5,733 million and about 46.3% to RMB 4,908 million, respectively; and after adjusting for share-based compensation expenses, foreign exchange gains and losses, equity investments, asset sales, restructuring gains and losses, and related one-time costs, the company’s non-IFRS adjusted net profit will grow by approximately 22.0% to RMB 6,586 million.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.